42nd Annual Miami Breast Cancer Conference: The Show and After Show

News
Video

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

For over 4 decades, the annual Miami Breast Cancer Conference (MBCC) has served as a premier gathering for multidisciplinary experts committed to improving breast cancer care.

Hosted by Physicians’ Education Resource (PER), MBCC 2025 continues its legacy by bringing together medical, surgical, and radiation oncologists, geneticists, pathologists, and radiologists to share cutting-edge advancements and best practices.

This year’s conference agenda includes deep dives into genomic and molecular biomarkers, precision oncology, imaging techniques, and adverse event management—ensuring that attendees gain the latest insights to enhance patient outcomes. Additionally, dedicated sessions for oncology nurses and advanced practice providers will cover critical topics such as sexual health, palliative care, and patient communication strategies.

Key highlights of MBCC 2025 are The Patti Hennessy Keynote Address, featuring Jamil Weaver, a 2-time breast cancer survivor and advocate for The Breasties, as well as the Scientific Keynote by Dr Felicia Knaul, who will shed light on the often-overlooked financial and emotional burdens of breast cancer.

For patients and caregivers, the Educated Patient Breast Cancer Summit, hosted by CURE, provides invaluable knowledge on biomarkers, genetic testing, and treatment advancements.

With its “Hear it on Friday, use it on Monday” approach, MBCC continues to be a must-attend event, ensuring that every medical professional leaves with actionable insights to enhance their practice. Whether in-person or virtual, MBCC 2025 promises to be an invaluable experience for all dedicated to the fight against breast cancer.

Join us at the legendary Fontainebleau Miami Beach and be part of the future of breast cancer care.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Related Content